In this section
@article{Forlano:2022:10.3390/ijms23158307,
author = {Forlano, R and Sivakumar, M and Mullish, BH and Manousou, P},
doi = {10.3390/ijms23158307},
journal = {International Journal of Molecular Sciences},
pages = {8307--8307},
title = {Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review},
url = {http://dx.doi.org/10.3390/ijms23158307},
volume = {23},
year = {2022}
}
TY - JOUR
AB - <jats:p>Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacteria play a crucial role in the pathogenesis and progression of liver damage in patients with NAFLD, it has been suggested that manipulating the microbiome may represent a therapeutical option. In this review, we summarise the latest evidence supporting the manipulation of the intestinal microbiome as a potential therapy for treating liver disease in patients with NAFLD.</jats:p>
AU - Forlano,R
AU - Sivakumar,M
AU - Mullish,BH
AU - Manousou,P
DO - 10.3390/ijms23158307
EP - 8307
PY - 2022///
SP - 8307
TI - Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
T2 - International Journal of Molecular Sciences
UR - http://dx.doi.org/10.3390/ijms23158307
UR - http://hdl.handle.net/10044/1/98535
VL - 23
ER -
For any enquiries about the Microbiome Network at Imperial, please contact: